The Role of Multimodality Cardiovascular Imaging

Renella, Pierangelo; Lai, Wyman W.; Prakash, Ashwin

doi:10.1002/9781119612858.ch47

Cited by 1 publication

(2 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The challenges involved in imaging CHD include (1) complex intracardiac and extracardiac vascular anatomy, (2) requirement for high temporal and spatial resolution, (3) need for repeated examinations over a lifetime, (4) anesthesia in younger patients and some older patients, (5) and regional variability in CMR availability and/or CHD expertise. These, and other challenges, can potentially be addressed through the use of ferumoxytol [ 6 , 8 , 18 , 24 , 41 , 45 ].…”

Section: Ferumoxytol-enhanced Mra (Fe-mra) and 4d Phase Contrast Mri ...mentioning

confidence: 99%

“…CMR/MRA is a 3D cross-sectional technique with a large field of view and clear extracardiac anatomic reference landmarks including the sternum, spine, and airways. Thus, CMR/MRA allows for the “on axis” display of ECG-gated dynamic (“cine”) images and can lead to more accurate definition of complex anatomy and measurement of cardiovascular structures [ 8 , 9 ]. Beyond anatomic and functional assessment, phase contrast MRI also allows for physiologic assessment of arterial and venous blood flow, intracardiac flow patterns, flow across heart valves, and shunt quantification [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ferumoxytol-Enhanced Cardiac Magnetic Resonance Angiography and 4D Flow: Safety and Utility in Pediatric and Adult Congenital Heart Disease

Renella

Prosper³

et al. 2022

Children

View full text Add to dashboard Cite

Cardiac magnetic resonance imaging and angiography have a crucial role in the diagnostic evaluation and follow up of pediatric and adult patients with congenital heart disease. Although much of the information required of advanced imaging studies can be provided by standard gadolinium-enhanced magnetic resonance imaging, the limitations of precise bolus timing, long scan duration, complex imaging protocols, and the need to image small structures limit more widespread use of this modality. Recent experience with off-label diagnostic use of ferumoxytol has helped to mitigate some of these barriers. Approved by the U.S. FDA for intravenous treatment of anemia, ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that has a long blood pool residence time and high relaxivity. Once metabolized by macrophages, the iron core is incorporated into the reticuloendothelial system. In this work, we aim to summarize the evolution of ferumoxytol-enhanced cardiovascular magnetic resonance imaging and angiography and highlight its many applications for congenital heart disease.

show abstract